

AroCell AB gets a Notice of Allowance in Japan

AroCell announces today that the Japanese Patent Office has issued a Notice of Allowance in the patent application No. 2016-541139 with the title "Monoclonal anti-TK1 antibodies".

The patent application relates to AroCell's proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. These antibodies are used in the AroCell TK 210 ELISA kit.

"We are delighted that we have got a Notice of Allowance in Japan for this patent application. This means that the chance is high for the patent to be granted in the near future. This will reinforce our patent position and attractiveness as a business partner in Asia. We will continue to develop our portfolio of proprietary assets to further expand its business opportunities and to support our product AroCell TK 210 ELISA," says Michael Brobjer, CEO AroCell.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Press Release
29 May 2020 13:45:00 CEST



Attachments

[AroCell AB gets a Notice of Allowance in Japan](#)